[Reprint] famous Chinese listed companies competitive _ III Tanhua lang

Original address: famous florida accident attorneyChinese listed companies core competitiveness analysis author: Paradise renowned Chinese companies listed on the value of core combeverly hills plastic surgerypetitiveness analysis 1, Tong ren Tang (600085): tongrentang is China's first brand of traditional Chinese medicine has 300 years of history, 200 years of independence during the Qing dynasty Government Office of medicine, and as the Zhongnanhai medication supply units, tongrentang production techniques and recipes from the national executive protection and enjoyment of the right quality policy. Tong ren Tang with proprietary 21 formulations, 400 species of varieties, including most fellow Wuji baifeng Wan and Liu Wei di Huang Wan, bezoar heart pills, bezoar pills, large bolus, State public wine, etc. Tongrentang pharmaceutical will seek meaures, in compliance with regard to ancient processing very seriously, and ornate, branded, quality of accredited degree is high, and most products catalogs entry into the national health insurance. In traditional Chinese medicine modernization and internationalization process, spearhead tongrentang has not only fully implemented the GMP transformation, respectively in Jilin province, Hubei Province, Shanxi province, Zhejiang, Henan, Hebei, Chinese herbal medicines for the GAP base; not only focus on the traditional products of the second development, also focused on new product development; in Hong Kong split listing of Tong ren Tang technologies also actively borrowed from international capital and technological strength and management experience; tongrentang developed a "firm towards Europe, Asia, the Americas, Oceania permeated" overseas expansion strategy, making full use of the flagship advantage to brand as intangible assets, shares, respectively in Hong Kong, United States, Australia, Thailand, Taiwan set up a joint venture or pharmacies, and from a simple product sales conversion to local production; export product quantity tongrentang from 20 up to now more than 130. Tongrentang through the development of the retail chain, breaking the previous pattern of passive marketing not only established a sound marketing network, has also contributed to the scale of key species. However, because of the relatively conservative management thinking and management mechanism is not perfect, there are still many potential products and product potential market has not yet been effective development. 2, Yunnan baiyao (000538): Yunnan baiyao is Yunnan province's largest proprietary production and pharmaceutical wholesale and retail enterprises, exclusive monopoly "Yunnan baiyao" production, "Chinese old" brand value outstanding. Yunnan baiyao capsule, powder for the protection of varieties at national level herbs (administrative protection period 1995.8.17-2015.8.17), Yunnan baiyao tincture, cream and white drug development for the prescription of blood Ning capsule to State second TCM protected varieties (1995.8.17-2002.8.17), Yunnan baiyao aerosol, Yunnan baiyao chuangketie, new products, the company has 17 products to enter the national essential drugs list "medical insurance. The company has established a base of wuding medicinal plant. The company is equipped with the postdoctoral workstation, scientific research investment and new product reserves and the management remains slightly weak. 3, donkey-hide gelatin (000423): donkey is the largest (output and exports respectively accounted for 75 per cent and 95 per cent), the most advanced technical equipment, quality best donkey-hide gelatin manufacturing enterprises, has a "crude (donkey skin) and the unique advantages of water resources" and authentic origin of brand value, brand of the "East" in March 2002 was recognized as China well-known trademarks. In the play "donkey-hide gelatin" traditional values at the same time, the company began to infiltrate biological high technology field, set the pharmaceutical, biomedical, health food, medicinal materials as one of the industrial layout, and forms to "blood (white blood cells, red blood cells, platelets), Thrombolysis," as the product system, but at present 84.6 per cent of the revenue and profit 90.4 percent comes from ejiao series. Donkey-hide gelatin not only focus on technological innovations on yield and quality of donkey-hide gelatin, also focused on biotechnology on traditional donkey-hide gelatin active ingredients, mechanisms, techniques, forms, new indications, such as the secondary development but a weaker independent research and development ability. The company is currently the only passed ISO14001 international environment system certification of Chinese enterprises, and also passed the ISO9000 quality system certification and the GMP production quality management standard certification for exports and foreign cooperation to lay a solid foundation. Leading product-gum-gum and compound mixture into category b non-prescription drugs, hospital, pharmacy, general store and supermarket sales. Although the company started in 2001 to increase marketing efforts, but at present marketing still weak. 4, 9-Tong (000989): Ltd.HR Hall is owned "Chinese old" of medium-sized Chinese production and pharmaceutical wholesale and retail enterprises, whose predecessor was established in the year 1650 old nine-Chi-Tang herbal pharmacy, there are 300 years of history, the brand value. The company's two leading products is the God of Wrigley lujiao gelatin powder and Shiba brand HB Ning granules (granules), former State second TCM protected varieties, national essential drugs, China Chinese famous brand product in Hunan province, is the only annual sales of over 1 billion Chinese varieties, but because the technology is still using the "traditional open pot roast rolling of skin manual" in size, quality, efficiency, profitability and other aspects behind the donkey-hide gelatin "c-leg steam ball of machine and steam pressure of leather technology." HB-Ning granules for State second TCM protected varieties, national essential drugs, Ministry of health, to specify the preferred treatment of chronic hepatitis proprietary Chinese medicines. At present the company in Hunan Changsha Ltd.HR Hall show 18, of which 3 sales companies, 2 distribution centers, pharmacies 13 (national second trans-regional chain). Ltd.HR Church as "Chinese old" in the property relations take the lead on "retreating" reform, but because of the scientific research and development of relatively weak, short term lack new profit growth point. 5. yangfan Pavilion (000591): yangfan Pavilion is the visitants brand, has a "South yangfan Pavilion, North tongrentang". Yangfan Pavilion's development strategy is "large" traditional Chinese medicine, large circulation, with 400 many kinds of proprietary varieties and 11 species of protected varieties of national herbal medicine, the main products is sinusitis oral liquid, shenglixiong pills, Chang'e Margareta Wahlstr?m pills, eight are mixture, bear Shu throat tablets, and other enrichment Maru series (yinqiao attenuated pills, liuwei dihuang Wan and qijudihuang pills, etc), which has been cited by sinusitis oral solutionFrom GlaxoSmithKline's grave concern and cooperative enthusiasm; yangfan Pavilion medicines market is by the national approved 17 Chinese professional trading market of Chongqing municipality only legitimate business market, and is the only enterprise of Chinese professional trading market; yangfan Pavilion in circulation has formed the "allocation, retail, wholesale," three-in-marketing system, has formed the "200 direct store + 932 home store" chain pattern and will establish a "chain network, logistics network, e-commerce network" triple operational mode. As a result of Chongqing medicinal herbs rich in resources, but also in Central and Western medicines distribution center, yangfan Pavilion in the development of pharmaceutical and medicinal herbs planting base has a unique geographical and resource advantages. In addition, yangfan GE shareholder taiji Group (600129) strength, has a strong marketing, research and development, management and capital operation advantages. However, yangfan Pavilion facing medicine workshop GMP transformation and large-scale investment medicine chain-like the funds, capital and return on investment. 6, Guangzhou pharmaceutical (600332): Guangzhou pharmaceutical iMortgage Loans Bad Credit ndustry is one of the largest proprietary enterprise, is concentrated drug production and pharmaceutical business as one of the largest pharmaceutical trading company, owns the "pangaoshou chenliji," "," "production-such as forests," "Chinese old" brand and production 500 kinds of products, of which 40 herbal protected varieties, 20 for the exclusive production. 2001 annual sales of over 1 billion yuan in three varieties, more than 5000 $ 5, $ 10 million over 30, the treatment of diabetes in Western medicine mixture "of diabetes pills" single varieties sales of more than $ 300 million, the market share as high as 16%. Guangzhou pharmaceutical belongs to the competent Chinese retail pharmacy chains and Chi Lin main Western retail chain of Jianmin pharmaceutical have separately owned at least 190 and 104 stores in national medicine chain sales rankings ranked seventh respectively and IV. Guangzhou pharmaceutical has H shares and A unit, business management, scientific research and development and marketing of modernization and internationalization of higher degree, plus size, brand, product line, and other advantages that make up the core competence of Guangzhou pharmaceutical industry, but the relative dispersion of the product structure is detrimental to the company to strengthen the focus on product development. 7, zhongxin pharmaceutical (600329): zhongxin pharmaceutical focused drug production and pharmaceutical business as a whole, have "lerentang" and "darentang" and so on many Chinese old. The company's existing 432 than traditional registered product (including darentang product 221 species), 100 kinds of products included in the national Medicare drug directory, there are 10 kinds of the CPI. Sales revenue of more than 2000 million varieties of 11, accounted for sales of 70-80 per cent, representative varieties are suxiao jiuxin 9 jinqi, yingqiaojiedu tablets, Hippocampus bushen nine buck IX, bezoar AGASTACHE soft-SAC, suxiao jiuxin Wan's annual sales of more than 2 billion, is a State secret products (3) and the National Hospital of necessary emergency medicine (the first batch of total 15). The company owns all over the country's raw materials procurement, pharmaceutical sales network as well as the monopoly of the retail network, Tianjin (new pharmacy and darentang, scale in the nation), the company respectively, 22-30 per cent share in the Sino-Smith and Sino-us better, accumulated the rich experience of foreign capital in joint cooperation, at the same time the company was the first release S unit (Singapore listing), formed a good corporate governance, accounting system and technological innovation system. But as the old state-owned enterprises precipitation phenomenon seriously, the company's marketing and management level remains to be improved. 8, Kunming pharmaceutical (600535): Kunming pharmaceutical walk is a "in accordance with international norms, from a single traditional Chinese medicine extraction of active ingredients in the" new drug development road, the main product of artemether and injection of the production process and acts of extraction and separation techniques is a State secret technology project, is a type of medicine with Western countries (in theory can also be reported to a class of drug, herbal medicine, by its very nature is natural medicine). Penny's ether has formed artemether API, artemether injection, (compound) artemether tablets, artemether capsule products are now registered in 27 countries, with annual sales of more than 300 million in outside sales, ranking China's independent invention of single agent drug exports. Other series products have Sanchi (in-depth development of Panax), tianma, breviscapine, etc. Companies with strong research and resource advantages, as well as a wealth of experience in foreign cooperation, currently has 13 State-level drug, where a class of drug 5, accounting for China's independent development of new drugs to the total number of 1/7; in addition the company also actively use modern biotechnology "cell culture paclitaxel," and "development of liposome", but the company's marketing efforts are relatively weak, management mechanism slightly conservative. 9, Jinling pharmaceutical (000919): Jinling pharmacy by five army Enterprise (Jinling pharmaceutical factory, Nanjing Jinwei natural feed company, Fuzhou Mei-feng pharmaceutical factory, Zhejiang TfL pharmaceutical factory, Hefei Li min pharmaceutical factory) combined to form, is a national high-tech enterprise, with State-level large-scale enterprise technology center. Company production of mailuoning (protection period extended until June 7, 2008), is the history of Chinese medicine in China by anointing, pill, powder, decoction to intravenous injection of a revolution, is the national medical insurance directory and the National Hospital of essential drugs, single emergency variety sales years maintained at more than 3 billion. New product-the "spot" (drug access size of cosmetics) successfully listed is expected to change in the company's current product mix too single phenomenon, the new analgesics for pain "Jun" has passed three injections during clinical trials, pending fingerprint quality control standards. The company also established in compliance with the GAP specification Dendrobium planting base and mast child planting base. Due to high volatility in recent years the company, company management and public image be negatively affected, but with the high authority of the place, the business situation should be able to receive a positive difference. 10, sanjiu pharmacy (000999): sanjiu pharmacy by virtue of "sanjiu weitai" and "zhuanggu joint pill" and "being day pill" 3 products, in the field of medicine pioneered "knowledge marketing" and "brand strategy", just a 10-year development become modern large pharmaceutical corporations, with Shenzhen 999 weitai series, sanjiu coldSpirit series, head holding of series, sanjiu Dermatitis, Radix paeoniae Alba glycosides-SAC, zhuangguguanjie pills, as day pill, senmai and more than 20 varieties as well as electronic leveling Cabinet, Chinese herbal medicine-medicine granules, new concept and a traditional Chinese medicine, sounded "999" well-known brand characteristics management mechanism and marketing network. As a result of product structures decentralization, the product relatively mature, market environment changing, capital expansion too quickly, structure, governance is not perfect, and other factors, the company benefits from years of decline. On this basis, the company adjusts the development strategy, the focus of the profits from production areas of shifted to the area of services, developed by "to the hospital with medicine, promote Chinese medicine world market" as the core content of the "modernization of traditional Chinese medicine, Chinese medicine industry, health care, the development strategy of": through the acquisition, merger integration of Chinese medicine clinics scattered abroad, establishing a thousand chain to the hospital with medicine, promote to the world of medicine, promote the industrialization of Chinese medicine; medicinal herbs from the planting �� yaan sanjiu, deyang sanjiu planting base of Chinese medicinal materials, to the pharmaceutical production, sales and followed suit, boiling, route of administration and so on each link to modernize, promote the modernization of traditional Chinese medicine; in-depth community health service network, with Shenzhen 999 chain drugstore networks, distribution networks and drugs 39 999 Chinese medicine clinic network, sanjiu health network "triple", expanding the space industry. And "pharmaceutical production, medicine chain-like, health services," and other aspects of resources, intended to new market conditions following the establishment of new operational pattern and profit model. 11, taiji Group (600129): taiji group to advance the "marketing" and "reverse flow of water technology innovation" as a principle, ranked second in the traditional industries (2000), the national pharmaceutical industry, and the tenth record "jizhi syrup" single variety of sales over $ 500 million in sales. But the Taiji group does not stick to a single traditional Chinese medicine industry, it is reasonable to renounce Chinese traditional medicine industry strengths and difficulties attracting international pharmaceutical innovations, grasping the world pharmaceutical development pattern, use their marketing management expertise, effective medicine industry management and capital operation as well as the "Western and Chinese traditional medicine" and "strategic alliance" formed "Western and Chinese business interactive development" and "Big Pharma" pattern (currently listed companies taiji group "yangfan Pavilion" and the "Southwest pharmaceutical" company, "yangfan Pavilion" subordinate "Sichuan tiancheng pharmacy" is intended to separate listing). Experienced 1998-2000 product restructuring, sales channel adjustment, industrial structure consolidation and scientific research strength reserves (national-level enterprise technical centers, 13 postdoctoral work sub-station, zhongqingzhongyaoyanjiuyuan, taiji Pharmaceutical Research Institute, at home and abroad for more than 30 renowned research institutes, as well as over 100 expert cooperation), taiji group 2001 ushered in a new round of growth, growth came mainly from �� national class �� qumei "weight" (Western medicine, 2001, sales of over $ 300 million), and Western medicine theory bushen rejuvenation pure herbs "bushenyishou capsule" (national essential drugs, 2001 sales of $ 100 million), the national five natural Gastric motility "new drugs" and AGASTACHE oral anticancer drugs "granisetron hydrochloride (Western)" and "paclitaxel (nature medicine)", "sleeping treasure health products (chemical synthetic)" as well as the treatment of diabetes national class I of rosiglitazone "new drugs" (Western); the company has established the country's largest chain management network (yangfan Pavilion pharmacy, tiancheng pharmacy, Sichuan Tai pharmacy 500 chain drugstore and joined the franchise pharmacies, etc.), standardized scientific logistics distribution center (pharmaceutical wholesale business, zigong, Sichuan, Chengdu joint pharmaceutical co., Ltd.), most portfolio of professional marketing team (2 000 sales staff), the most successful new product launch planning (successfully started "qumei"), the most powerful drugs agency capital (agent Bayer products), the company "comprehensive system of marketing management" was awarded the 2000 annual "national-level modernization of enterprise management innovation achievement award". "Promoting Chinese medicine industry towards international" remains the Taiji Group's long-term development strategy, the company established by the Institute of traditional Chinese medicine culture is responsible for 10 million acres of standardized planting base of Chinese medicinal materials GAP (gastrodia ELATA rhizoma pinelliae, chuanxiong, etc), also use the "Chinese and Western cultures" of Macao and the "natural medicine leading" Germany as "internationalization window". As the industry's expansion and diversification of development, the Taiji group management's management capacity and thinking are need to synchronize the development, management and financial ability to continue to strengthen. 12, day of the GEO (600535): Tian Li Shi devoted to prevention, treatment and cerebrovascular disease-oriented series drugs in development, production and sales as well as the cultivation and processing of traditional Chinese medicine. At present the company 85 per cent of the income and 95 per cent of the profits are derived from Salvia, Salvia series products formed the "pills" feature. Company of another product for yangxueqingnao. Salvia and granules are prescription drugs, are entered into the national essential drugs list "medical insurance, the former is the CPI, which for the CPI. Tian Li Shi of Salvia positioning in the high-end market, gross profit margin at 65 per cent, but the corresponding cost huge erode profits, Tian Li Shi's marketing and management level is to be improved. Tian Li Shi "product structure single, investment recovery slow, family holding heavier, core technology minority master, pills-there are a number of production, Diwan is difficult to become a technology platform, as well as traditional Chinese medicine industry internationalization course difficult", and so there are potential pressure. 13, aodong (000623): jilinaodong is located in the Changbai mountain area around, is based on traditional Chinese medicine industry, set the aquaculture industry, printing industry, Commerce, services, securities, real estate is one of the diversified investment holdings company, is a national key high technology enterprises. In traditional Chinese medicine and Chinese medicinal herbs cultivation farming areas, the company has four National Center (national-level enterprise technical centers, post-doctoral, agricultural industrialization tap enterprise, sika deer breeding base), the production scale of Asia's first deer breeding base are Chinese pharmaceutical association named hortulorum aquaculture demonstration base, also get velvet efficient farming value-added technology of Jilin province science and technology progress second prize. In addition, the company also has mountain green herbs bases, KyrgyzstanLin province in Prairie Plant medicine development research base, Sichuan Wuxi medicinal herbs ingredients and processing bases, Zhuhai marine medicine production base and 4 ginseng plantation, etc. At present, the base is implemented in accordance with international norms GAP standards. Most "anshenbunao" after years of technical quality competition and ultimately become jilinaodong exclusive production varieties. Therefore, crude and rich herbal resources, powerful new product development and marketing strength firmly constitute jilinaodong's core competitiveness. 14, tonghua dongbao (600867): tonghua dongbao first merger rural, collective enterprise merger SOE tunes and in the spirit of "cross-industry, cross-regional and TRANS-international development" ideas from health tonic to therapeutic drugs, traditional medicine to biotechnology drugs, the pharmaceutical industry to leap in the field of plastic building materials �� 1994 to medicines "town of cerebral Ning capsule" and "Toho liver slices" from health tonic to therapeutic drugs in transition, and promote company 1994-1996 for three consecutive years and high growth ("the town of single brain Ning has set" variety 1.5 billion in annual sales revenue); 1995, "recombinant human insulin" countries 1995 research plan, has invested $ 200 million in October 1998, developed China's first recombinant human insulin, making China one of the world and the third to the production of genetically human insulin, and has applied for international patent. 2002 investment 1.99 billion launched a State-level high-tech industrialization project "recombinant human insulin in high-tech model works"; in 2001, tonghua dongbao implements gene insulin raw 1000 million of exports; in the second half of 2002, the company began exporting to Egypt gene insulin preparations distance (3-year contract $ 3600 million), and to carry out export since 2003 Russia's 5-year contract, involving 5278 million; as of 10 October 2002, tonghua dongbao has to Egypt export of recombinant human insulin design amount 386.4 million, was completed in the second half of 2002, Egypt $ 6 million orders 64.4 per cent, which is the amount of foreign exchange to 84 million (i.e. 694 million RMB). In addition, the company early in 1996, plans to invest $ 1.9 billion in the fourth generation NO-PVC infusion, is now officially put into operation in 2000. Jilin tonghua dongbao is a high-tech enterprises, long-term innovation spirit should be tonghua dongbao core competitiveness, but as the project difficult, is in a restructuring phase, family management shortcomings as well as market and other factors, the economic benefits of these projects have not yet been fully reflected. 15, violet Guhan (000590): violet Guhan predecessor Hunan ancient Chinese group, calendar management is a "culture of Mawangdui". It is said that its most "precise" ancient Chinese health is based on the Changsha Mawangdui Millennium ancient tomb of the health side of dense purpose in 1986 developed (for national security prescriptions), first pioneered the concept of "health and medicine" by a long-standing culture of maintaining a lift that ancient Chinese health actuarial rapid spread, with annual sales of more than 1 billion. As the product of a single, subsequent new product development and investment has errors, the ancient Chinese group in 2000 were qinghuaziguangjituan acquisitions, and renamed as "bio", after the violet to continue to promote the "ancient Han" brand, once again changed its name to "Violet ancient Chinese". 16, taitai (600380): field of the health care establishment "brand reputation" and "developed marketing system" taitai, in 2001-2002 period, through the acquisition of health pharmacy, lizhu group relative controlling stake and the use of meditation oral "kin-font size change font size" opportunity allowed, from health care to a strategic shift in the field of medicine. Taitai will health products marketing experience porting to non-prescription drugs (PCM) of marketing, has the potential to create proprietary sales in China. In addition, as a private, family, wife of modern enterprise management in the pharmaceutical industry, talent introduction and introduction of technology are extremely flexible and efficient, but because we are weak, the pharmaceutical industry has not yet been formed independent research and development strength.